136 related articles for article (PubMed ID: 23879002)
21. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
22. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.
Jones-Hughes T; Snowsill T; Haasova M; Coelho H; Crathorne L; Cooper C; Mujica-Mota R; Peters J; Varley-Campbell J; Huxley N; Moore J; Allwood M; Lowe J; Hyde C; Hoyle M; Bond M; Anderson R
Health Technol Assess; 2016 Aug; 20(62):1-594. PubMed ID: 27578428
[TBL] [Abstract][Full Text] [Related]
23. [Effectiveness and safety of conversion therapy with the combination of sirolimus with low dose cyclosporine in renal transplantation recipients: a five-year clinical observation].
Zhu L; Ding T; Wang XX; Lin ZB; Chen G
Zhonghua Yi Xue Za Zhi; 2016 May; 96(20):1556-61. PubMed ID: 27266681
[TBL] [Abstract][Full Text] [Related]
24. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
Spagnoletti G; Citterio F; Favi E; Rossi E; Delreno F; De Santis I; Salerno MP; Gargiulo A; Castagneto M
Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
[TBL] [Abstract][Full Text] [Related]
26. Randomized trial of cyclosporine and tacrolimus therapy with steroid withdrawal in living-donor renal transplantation: 5-year follow-up.
Lee YJ; Kim B; Lee JE; Kim YG; Kim DJ; Kim SJ; Joh JW; Oh HY; Huh W
Transpl Int; 2010 Feb; 23(2):147-54. PubMed ID: 19744223
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
[TBL] [Abstract][Full Text] [Related]
28. [Infectious complications in using mofetil micofenolate in patients with renal allotransplant].
Prokopenko EI; Shcherbakova EO; Vatazin AV; Kruglov EE; Pasov SA; Budnikova NE; Agafonova SG; Rusanova EV
Ter Arkh; 2005; 77(1):67-72. PubMed ID: 15759459
[TBL] [Abstract][Full Text] [Related]
29. Minimization of maintenance immunosuppressive therapy after renal transplantation comparing cyclosporine A/azathioprine or cyclosporine A/mycophenolate mofetil bitherapy to cyclosporine A monotherapy: a 10-year postrandomization follow-up study.
Thierry A; Le Meur Y; Ecotière L; Abou-Ayache R; Etienne I; Laurent C; Vuiblet V; Colosio C; Bouvier N; Aldigier JC; Rerolle JP; Javaugue V; Gand E; Bridoux F; Essig M; Hurault de Ligny B; Touchard G
Transpl Int; 2016 Jan; 29(1):23-33. PubMed ID: 26729582
[TBL] [Abstract][Full Text] [Related]
30. Modifying cyclosporine associated renal allograft dysfunction.
Mohapatra N; Vanikar AV; Patel RD; Trivedi HL
Saudi J Kidney Dis Transpl; 2009 Sep; 20(5):770-4. PubMed ID: 19736471
[TBL] [Abstract][Full Text] [Related]
31. Immunosuppression modifications and graft outcome in patients with chronic allograft nephropathy.
El-Agroudy AE; El-Dahshan K; Mahmoud K; Ismail AM; El-Baz M; Shokeir AA; Ghoneim MA
Exp Clin Transplant; 2008 Sep; 6(3):203-10. PubMed ID: 18954298
[TBL] [Abstract][Full Text] [Related]
32. Gastrointestinal disorders after renal transplantation.
Savvidaki E; Papachristou E; Kazakopoulos P; Papasotiriou M; Vardoulaki M; Goumenos DS
Transplant Proc; 2014 Nov; 46(9):3183-6. PubMed ID: 25420854
[TBL] [Abstract][Full Text] [Related]
33. Cryptosporidium infection after renal transplantation in an endemic area.
Bhadauria D; Goel A; Kaul A; Sharma RK; Gupta A; Ruhela V; Gupta A; Vardhan H; Prasad N
Transpl Infect Dis; 2015 Feb; 17(1):48-55. PubMed ID: 25620388
[TBL] [Abstract][Full Text] [Related]
34. Conversion from tacrolimus/mycophenolic acid to tacrolimus/leflunomide to treat cutaneous warts in a series of four pediatric renal allograft recipients.
Nguyen L; McClellan RB; Chaudhuri A; Alexander SR; Chen SF; Concepcion W; Grimm P
Transplantation; 2012 Sep; 94(5):450-5. PubMed ID: 22960763
[TBL] [Abstract][Full Text] [Related]
35. Lipid profile changes during the first year after kidney transplantation: risk factors and influence of the immunosuppressive drug regimen.
Spinelli GA; Felipe CR; Park SI; Mandia-Sampaio EL; Tedesco-Silva H; Medina-Pestana JO
Transplant Proc; 2011 Dec; 43(10):3730-7. PubMed ID: 22172836
[TBL] [Abstract][Full Text] [Related]
36. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A
Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603
[TBL] [Abstract][Full Text] [Related]
37. Potential cardiovascular risk factors in paediatric renal transplant recipients.
Ferraris JR; Ghezzi L; Waisman G; Krmar RT
Pediatr Nephrol; 2006 Jan; 21(1):119-25. PubMed ID: 16252106
[TBL] [Abstract][Full Text] [Related]
38. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
[TBL] [Abstract][Full Text] [Related]
39. Tacrolimus with mycophenolate mofetil or sirolimus compared with calcineurin inhibitor-free immunosuppression (sirolimus/mycophenolate mofetil) after heart transplantation: 5-year results.
Kaczmarek I; Zaruba MM; Beiras-Fernandez A; Reimann R; Nickel T; Grinninger C; Sadoni S; Hagl C; Meiser B
J Heart Lung Transplant; 2013 Mar; 32(3):277-84. PubMed ID: 23415313
[TBL] [Abstract][Full Text] [Related]
40. Malignancy after renal transplantation in the new era of immunosuppression.
Watorek E; Boratynska M; Smolska D; Patrzalek D; Klinger M
Ann Transplant; 2011; 16(2):14-8. PubMed ID: 21716180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
